Safety of High Doses of Urokinase and Reteplase for Acute Ischemic Stroke

تاریخ : ۱۳۹۲/۰۵/۱۴ / تعداد بازدید : ۲۲۴

BACKGROUND AND PURPOSE:

ET is considered in selected patients with AIS with persistent arterial occlusion after receiving IVT. Limited data exist on the safety of IA high doses of UK and RT for ET. We investigated any correlation between IA doses of UK or RT and safety outcomes in patients who underwent ET.

MATERIALS AND METHODS:

We identified all patients from our stroke registry who received UK or RT for ET from 1998 to 2008. Demographics, baseline National Institutes of Health Stroke Scale scores, recanalization rates, rates of attempted MT, mortality, SICH, and discharge modified Rankin Scale scores were collected.

RESULTS:

Of 197 patients; 72 received UK and 125 received RT. More than 90% of patients in both groups had received prior IVT. The median IA dose of UK was 200,000 U (range, 25,000–1,500,000 U) and of RT was 2 mg (range, 1–8 mg). Concurrent MT was attempted in 59.7% of UK-treated patients and 72.0% of RT-treated patients, with SICH rates of 4.2% and 8.0%, respectively. Logistic regression adjusting for prior IVT and MT revealed no correlation between SICH and doses of UK (OR, 1.00; 95% CI, 0.99–1.00; P .94) or RT (OR, 0.803; 95% CI, 0.48–1.33; P .39). There was no correlation between mortality and doses of UK (OR, 1.00; 95% CI, 0.99–1.00; P .51) or RT (OR, 1.048; 95% CI, 0.77–1.42; P .75).

CONCLUSIONS:

High IA doses of UK and RT may be safe when given with or without MT in patients with AIS despite receiving a full dose of intravenous recombinant tissue plasminogen activator. These results need prospective validation.

View full article here: Safety of High Doses of reteplase in stroke

آخرین مقالات

ثبت مشخصات

نام

پست الکترونیک

کپچا

دیدگاه

Safety of High Doses of Urokinase and Reteplase for Acute Ischemic Stroke

Phase III Dose-Comparison Study of Glatiramer Acetate for Multiple Sclerosis

دانستنی های مفید در خصوص حساسیت دارویی

دلایل و درمان سرگیجه

Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia

The Effectiveness of Dimethyl Fumarate Monotherapy in the Treatment of Relapsing-Remitting Multiple Sclerosi

Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing–remitting multiple sclerosis